Literature DB >> 23622801

Penbactam for Helicobacter pylori eradication: a randomised comparison of quadruple and triple treatment schedules in an Iranian population.

Seyedali Seyedmajidi1, Dariush Mirsattari, Homayoun Zojaji, Elahe Zanganeh, Mohammadreza Seyyedmajidi, Shohreh Almasi, Mohammadreza Zali.   

Abstract

BACKGROUND & STUDY AIMS: Selection of the best drug regimens for eradication of Helicobacter pylori infection especially in patients at risk of peptic ulcer relapses and the development of complications is challenging. This study assessed and compared the efficacy of the two common PPI based triple therapies to a quadruple therapy including PPI, metronidazole, amoxicillin and a bismuth compound in Iranian population. PATIENTS &
METHODS: Three hundred and thirty patients with peptic ulcer and H. pylori infection were included in the study. Patients were randomly assigned to one of the three treatment protocols all given twice daily: (a) A 14-day quadruple therapy (OMAB group) comprising omeprazole 20mg, metronicazole 500 mg, amoxicillin 1g, and bismuth subcitrate 240 mg; (b) A 14-day triple regimen (OCP group) comprising omeprazole 20mg plus clarithromycine 500 mg and penbactam 750 mg and (c) A 14-day triple regimen (OCA group) comprising omeprazole 20mg plus clarithromycine 500 mg and amoxicillin 1g. Cure was defined as a negative urea breath test at least six weeks after treatment.
RESULTS: The per-protocol eradication rates achieved with both OCP regimen (87.0%) and OCA treatment (90.8%) were significantly higher than the OMAB treatment protocol (56.0%); however, no significant difference emerged in eradication rates between the two triple treatment schedules. No significant differences between the groups were found in most side-effects.
CONCLUSION: Two-week quadruple therapy showed a lower eradication rate compared to common triple treatment schedules when used as first-line eradication treatment for H. pylori infection in Iranian population.
Copyright © 2012 Arab Journal of Gastroenterology. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23622801     DOI: 10.1016/j.ajg.2012.12.004

Source DB:  PubMed          Journal:  Arab J Gastroenterol        ISSN: 1687-1979            Impact factor:   2.076


  6 in total

1.  First-line therapy in Helicobacter pylori eradication therapy: experience of a surgical clinic.

Authors:  Gökhan Selçuk Özbalcı; Saim Savaş Yürüker; İsmail Alper Tarım; Hamza Çınar; Ayfer Kamalı Polat; Aysu Başak Özbalcı; Kağan Karabulut; Kenan Erzurumlu
Journal:  Ulus Cerrahi Derg       Date:  2014-09-01

Review 2.  Helicobacter pylori eradication in West Asia: a review.

Authors:  Hafez Fakheri; Zohreh Bari; Mohsen Aarabi; Reza Malekzadeh
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

Review 3.  Pharmacological therapy used in the elimination of Helicobacter pylori infection: a review.

Authors:  Ariolana A Dos Santos; Adriana A Carvalho
Journal:  World J Gastroenterol       Date:  2015-01-07       Impact factor: 5.742

4.  Addition of cranberry to proton pump inhibitor-based triple therapy for Helicobacter pylori eradication.

Authors:  Mohammadreza Seyyedmajidi; Anahita Ahmadi; Shahin Hajiebrahimi; Seyedali Seyedmajidi; Majid Rajabikashani; Mona Firoozabadi; Jamshid Vafaeimanesh
Journal:  J Res Pharm Pract       Date:  2016 Oct-Dec

Review 5.  Eradication of Helicobacter Pylori in Iran: A Review.

Authors:  Hafez Fakheri; Mehdi Saberi Firoozi; Zohreh Bari
Journal:  Middle East J Dig Dis       Date:  2017-09-21

6.  Addition of clidinium-C to the 14-day proton-pump inhibitor-based triple therapy for Helicobacter pylori eradication.

Authors:  Mohammadreza Seyyedmajidi; Saba Homapoor; Elahe Zanganeh; Mohammad Dadjou; Shahab Eskandari Nejad; Mohammad Hadi Tajik Galayeri; Jamshid Vafaeimanesh
Journal:  Caspian J Intern Med       Date:  2016
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.